Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Gemcitabine

Research Leaders

11 sponsors active, led by Asan Medical Center

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total

Phase 2 (2)

Phase 3 (1)

Trial Status

Unknown2

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials

NCT05149170Phase 2Unknown

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

NCT02085655Phase 3UnknownPrimary

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

NCT01238159Phase 2CompletedPrimary

Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma

Showing all 3 trials

Research Network

Common Treatments

Gemcitabine1
Antipd1 Monoclonal Antibody1
Dexamethasone1
Ccrtmidle Chemotherapy1
Pegaspargase1

Active Sponsors

Asan Medical Center1
Huiqiang Huang1
Affiliated Cancer Hospital & Institute of Guangzhou Medical University1
Sun Yat-sen University1
Chinese Academy of Medical Sciences1

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type